Immuneering Corp(IMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IMRX Immuneering Corp

未开盘 02-26 16:00:00 EST

4.99

-0.25

-4.77%

盘后4.96

-0.03-0.65%

19:47 EST

最高5.21	最低4.94	成交量67.49万
今开5.21	昨收5.24	日振幅5.15%
总市值3.22亿	流通市值2.72亿	总股本6,457万
成交额338.88万	换手率1.24%	流通股本5,441万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IMRX","market":"US","secType":"STK","nameCN":"Immuneering Corp","latestPrice":4.99,"timestamp":1772139600000,"preClose":5.24,"halted":0,"volume":674866,"hourTrading":{"tag":"盘后","latestPrice":4.9577,"preClose":4.99,"latestTime":"19:47 EST","volume":4915,"amount":24543.8771,"timestamp":1772153252523,"change":-0.0323,"changeRate":-0.006473,"amplitude":0.008477},"delay":0,"changeRate":-0.047709923664122134,"floatShares":54411779,"shares":64569967,"eps":-1.75688,"marketStatus":"未开盘","change":-0.25,"latestTime":"02-26 16:00:00 EST","open":5.21,"high":5.21,"low":4.94,"amount":3388804.9308876004,"amplitude":0.051527,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.75688,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772182800000},"marketStatusCode":0,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":5.24,"preHourTrading":{"tag":"盘前","latestPrice":5.28,"preClose":5.24,"latestTime":"09:15 EST","volume":884,"amount":4641.1592967999995,"timestamp":1772115317693,"change":0.04,"changeRate":0.007634,"amplitude":0.01145},"postHourTrading":{"tag":"盘后","latestPrice":4.9577,"preClose":4.99,"latestTime":"19:47 EST","volume":4915,"amount":24543.8771,"timestamp":1772153252523,"change":-0.0323,"changeRate":-0.006473,"amplitude":0.008477},"volumeRatio":1.089964,"impliedVol":0.9226,"impliedVolPercentile":0.2079},"requestUrl":"/m/hq/s/IMRX","defaultTab":"news","newsList":[{"id":"2603124529","title":"Immuneering Corporation盘中异动 股价大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603124529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603124529?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:30","pubTimestamp":1768228240,"startTime":"0","endTime":"0","summary":"北京时间2026年01月12日22时30分，Immuneering Corporation股票出现异动，股价大幅下跌5.26%。截至发稿，该股报4.41美元/股，成交量4.7832万股，换手率0.07%，振幅0.00%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.00%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223040a4bb0dd6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112223040a4bb0dd6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4539","BK4139","BK4563"],"gpt_icon":0},{"id":"2601333347","title":"优于标准疗法但仍不敌竞品 Immuneering(IMRX.US)胰腺癌疗法2期数据公布后盘后重挫21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601333347","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601333347?lang=zh_cn&edition=full","pubTime":"2026-01-08 09:01","pubTimestamp":1767834062,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物技术公司Immuneering Corp.在周三盘后交易中暴跌约21%，此前其公布了atebimetinib作为胰腺癌一线疗法的2a期临床试验结果。该公司报告称，接受atebimetinib联合改良版吉西他滨/白蛋白结合型紫杉醇治疗的患者，12个月总生存率为64%。Immuneering特别指出，在超过10%的患者中仅观察到两种3级不良事件，即中性粒细胞减少症和贫血。其中，avutometinib联合疗法此前报告的总缓解率达83%，daraxonarasib则为55%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390162.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"优于标准疗法但仍不敌竞品 Immuneering(IMRX.US)胰腺癌疗法2期数据公布后盘后重挫21%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4563","IMRX","BK4139","BK4539"],"gpt_icon":0},{"id":"1180103519","title":"Immuneering公布一线胰腺癌患者接受Atebimetinib联合Mgnp治疗的12个月总生存率高达64%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180103519","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180103519?lang=zh_cn&edition=full","pubTime":"2026-01-08 05:01","pubTimestamp":1767819675,"startTime":"0","endTime":"0","summary":"生物科技公司Immuneering Corp (IMRX) 发布了令人瞩目的临床数据，显示其研发的Atebimetinib与Mgnp联合疗法在一线胰腺癌患者群体中取得突破性进展。治疗组患者在12个月时间点的总生存率达到了惊人的64%，这一数据显著超越了现有标准疗法的预期效果。\n胰腺癌作为恶性程度极高的肿瘤类型，长期面临治疗选择有限、患者预后差的挑战。此次公布的生存率数据为这一疾病领域的治疗带来了新的希望，也凸显了Atebimetinib联合疗法的潜在临床价值。该结果可能为后续的注册临床试验奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4139","BK4563","BK4539"],"gpt_icon":0},{"id":"1123783511","title":"Immuneering将在2026年1月7日公布一线胰腺癌患者接受Atebimetinib + Mgnp治疗的2a期临床试验12个月整体生存数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1123783511","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123783511?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:02","pubTimestamp":1766494972,"startTime":"0","endTime":"0","summary":"Immuneering将在2026年1月7日公布一线胰腺癌患者接受Atebimetinib + Mgnp治疗的2a期临床试验12个月整体生存数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMRX","BK4563","BK4539"],"gpt_icon":0},{"id":"1137012656","title":"Immuneering公司推进III期Atebimetinib试验，目标为首例一线转移性胰腺癌患者给药，同时获得FDA和EMA的对齐","url":"https://stock-news.laohu8.com/highlight/detail?id=1137012656","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137012656?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:08","pubTimestamp":1766005735,"startTime":"0","endTime":"0","summary":"Immuneering公司推进III期Atebimetinib试验，目标为首例一线转移性胰腺癌患者给药，同时获得FDA和EMA的对齐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4539","IMRX"],"gpt_icon":0},{"id":"1162312611","title":"Immuneering预计将在2026年中期开始全球III期注册试验Mapkeeper 301的首位患者的给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1162312611","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162312611?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:07","pubTimestamp":1766005646,"startTime":"0","endTime":"0","summary":"Immuneering预计将在2026年中期开始全球III期注册试验Mapkeeper 301的首位患者的给药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4539","IMRX"],"gpt_icon":0},{"id":"2583639168","title":"Immuneering Corporation盘中异动 早盘大幅下挫5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583639168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583639168?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:32","pubTimestamp":1763130721,"startTime":"0","endTime":"0","summary":"北京时间2025年11月14日22时32分，Immuneering Corporation股票出现波动，股价大幅跳水5.43%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.13%。其相关个股中，Cidara Therapeutics, Inc.、Invivyd, Inc.、Aspire Biopharma Holdings, Inc.涨幅较大，Aspire Biopharma Holdings, Inc.、Clearmind Medicine Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为691.61%、36.15%、28.68%，振幅较大的相关个股有60 Degrees Pharmaceuticals, Inc.、Indaptus Therapeutics, Inc.、Mineralys Therapeutics, Inc.，振幅分别为14.53%、11.51%、10.85%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511142232019504b0db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511142232019504b0db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4563","IMRX","BK4139"],"gpt_icon":0},{"id":"2579443199","title":"Immuneering Corporation盘中异动 下午盘股价大涨5.04%报6.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579443199","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579443199?lang=zh_cn&edition=full","pubTime":"2025-10-31 01:12","pubTimestamp":1761844375,"startTime":"0","endTime":"0","summary":"北京时间2025年10月31日01时12分，Immuneering Corporation股票出现波动，股价快速拉升5.04%。截至发稿，该股报6.57美元/股，成交量44.9432万股，换手率0.71%，振幅7.36%。Immuneering Corporation股票所在的生物技术行业中，整体跌幅为0.67%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031011255974ab899&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031011255974ab899&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","BK4563","IMRX"],"gpt_icon":0},{"id":"2575568207","title":"Immuneering Corporation盘中异动 下午盘股价大涨5.20%报6.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575568207","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575568207?lang=zh_cn&edition=full","pubTime":"2025-10-16 03:11","pubTimestamp":1760555506,"startTime":"0","endTime":"0","summary":"北京时间2025年10月16日03时11分，Immuneering Corporation股票出现波动，股价急速上涨5.20%。截至发稿，该股报6.27美元/股，成交量110.26万股，换手率1.74%，振幅7.38%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.53%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101603114697303776&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101603114697303776&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","IMRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2575371852","title":"Immuneering Corporation盘中异动 大幅下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575371852","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575371852?lang=zh_cn&edition=full","pubTime":"2025-10-13 23:03","pubTimestamp":1760367828,"startTime":"0","endTime":"0","summary":"北京时间2025年10月13日23时03分，Immuneering Corporation股票出现异动，股价大幅下跌5.06%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、天境生物、Nanobiotix涨幅较大，Quoin Pharmaceuticals Ltd、Tvardi Therapeutics, Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为83.75%、43.01%、31.48%，振幅较大的相关个股有Carisma Therapeutics, Inc.、Cingulate Inc C/Wts 10/12/2026 、Yd Bio Ltd C/Wts 28/08/2030，振幅分别为32.42%、31.57%、27.69%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013230348972b7ac2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013230348972b7ac2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","IMRX","BK4539","BK4139"],"gpt_icon":0},{"id":"2572559182","title":"Immuneering Corporation盘中异动 早盘急速下跌5.14%报6.64美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572559182","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572559182?lang=zh_cn&edition=full","pubTime":"2025-10-01 22:07","pubTimestamp":1759327649,"startTime":"0","endTime":"0","summary":"北京时间2025年10月01日22时07分，Immuneering Corporation股票出现波动，股价大幅下挫5.14%。截至发稿，该股报6.64美元/股，成交量99.6637万股，换手率1.58%，振幅5.57%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为1.80%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001220729a45036e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251001220729a45036e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4539","BK4139","BK4563"],"gpt_icon":0},{"id":"1167720395","title":"Immuneering Corp将于2025年9月29日周一讨论Atebimetinib联合Mgnp治疗一线胰腺癌患者2a期临床试验的最新总体生存期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1167720395","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167720395?lang=zh_cn&edition=full","pubTime":"2025-09-27 04:01","pubTimestamp":1758916899,"startTime":"0","endTime":"0","summary":"Immuneering Corp计划于2025年9月29日周一就其最近公布的Atebimetinib联合Mgnp治疗一线胰腺癌患者2a期临床试验的总体生存期数据进行讨论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4539","BK4139","BK4563"],"gpt_icon":0},{"id":"1164778643","title":"Immuneering Corp宣布完成1.75亿美元A类普通股承销公开发行定价，同时向Sanofi进行2500万美元私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1164778643","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164778643?lang=zh_cn&edition=full","pubTime":"2025-09-25 12:09","pubTimestamp":1758773367,"startTime":"0","endTime":"0","summary":"Immuneering Corp宣布完成1.75亿美元A类普通股承销公开发行定价，同时向Sanofi进行2500万美元私募配售","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4539","BK4563","BK4139"],"gpt_icon":0},{"id":"1193887538","title":"Immuneering Corp宣布拟议承销公开发行A类普通股和预付费认股权证，同时向Sanofi进行A类和B类普通股私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1193887538","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193887538?lang=zh_cn&edition=full","pubTime":"2025-09-25 04:05","pubTimestamp":1758744315,"startTime":"0","endTime":"0","summary":"Immuneering Corp宣布，公司计划进行A类普通股和预付费认股权证的承销公开发行，同时向Sanofi进行A类普通股和B类普通股的私募配售。\n这一融资计划包括两个部分：首先是面向公众投资者的承销发行，涉及A类普通股和预付费认股权证；其次是与法国制药巨头Sanofi同期进行的私募配售交易，涉及A类和B类普通股。\n该公司此次融资举措旨在为其业务发展和研发项目提供资金支持。具体的发行规模、定价和时间安排等详细信息尚待进一步公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","IMRX","BK4563"],"gpt_icon":0},{"id":"1157786888","title":"Immuneering Corp宣布一线胰腺癌患者接受Atebimetinib + Mgnp治疗后9个月总生存率达86%的卓越成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1157786888","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157786888?lang=zh_cn&edition=full","pubTime":"2025-09-25 04:02","pubTimestamp":1758744144,"startTime":"0","endTime":"0","summary":"Immuneering Corp宣布一线胰腺癌患者接受Atebimetinib + Mgnp治疗后9个月总生存率达86%的卓越成果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4139","BK4539","IMRX"],"gpt_icon":0},{"id":"2566993612","title":"Immuneering Corporation盘中异动 股价大涨10.71%报7.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566993612","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566993612?lang=zh_cn&edition=full","pubTime":"2025-09-10 21:32","pubTimestamp":1757511128,"startTime":"0","endTime":"0","summary":"北京时间2025年09月10日21时32分，Immuneering Corporation股票出现异动，股价大幅上涨10.71%。截至发稿，该股报7.81美元/股，成交量22.5808万股，换手率0.54%，振幅6.38%。Immuneering Corporation股票所在的生物技术行业中，整体跌幅为0.48%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250910213208a71bf764&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250910213208a71bf764&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4563","BK4539","IMRX"],"gpt_icon":0},{"id":"1141181627","title":"Immuneering Corp将于9月25日公布Atebimetinib + Mgnp治疗一线胰腺癌患者2a期临床试验的最新总生存期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1141181627","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141181627?lang=zh_cn&edition=full","pubTime":"2025-09-10 19:02","pubTimestamp":1757502131,"startTime":"0","endTime":"0","summary":"Immuneering Corp将于9月25日公布Atebimetinib + Mgnp治疗一线胰腺癌患者2a期临床试验的最新总生存期数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMRX","BK4539","BK4139","BK4563"],"gpt_icon":0},{"id":"1142181606","title":"Immuneering宣布完成2500万美元私人配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1142181606","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142181606?lang=zh_cn&edition=full","pubTime":"2025-08-27 04:10","pubTimestamp":1756239034,"startTime":"0","endTime":"0","summary":"马萨诸塞州剑桥，2025年8月26日——专注于延长癌症患者生命的临床阶段肿瘤公司Immuneering Corp今日宣布完成此前公布的私人配售。此次私人配售面向顶级机构投资者和合格投资者，扣除费用和开支前的总收益约为2500万美元。Leerink Partners担任Immuneering此次私人配售的财务顾问。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4539","IMRX"],"gpt_icon":0},{"id":"1108193013","title":"Immuneering Corp宣布与礼来签署临床供应协议，评估Atebimetinib联合Olomorasib的疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1108193013","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108193013?lang=zh_cn&edition=full","pubTime":"2025-08-25 20:04","pubTimestamp":1756123444,"startTime":"0","endTime":"0","summary":"Immuneering Corp宣布与礼来签署临床供应协议，双方将联合评估Atebimetinib与Olomorasib的组合疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0238689110.USD","LU1069344957.HKD","LU2089984988.USD","LU1093756325.SGD","LU0203201768.USD","LU0882574139.USD","SG9999018865.SGD","LU1280957306.USD","LU0471298777.SGD","LU0882574055.USD","LU2491049909.HKD","LU0058720904.USD","LU2461242641.AUD","LU0823434740.USD","LU2264538146.SGD","GB00BDT5M118.USD","LU2750360997.AUD","LU1868836757.USD","LU2237443549.SGD","LU2471134952.CNY","LU0320765059.SGD","BK4516","LU0316494557.USD","SG9999017495.SGD","LU0094547139.USD","LU2211815571.USD","LU0061475181.USD","LU0466842654.USD","LU2237443622.USD","SG9999015952.SGD","LU0820561818.USD","LLY","SG9999015986.USD","LU1061106388.HKD","LU2237443978.SGD","LU2265009873.SGD","LU2468319806.SGD","LU2471134796.USD","LU0786609619.USD","LU0109394709.USD","LU0385154629.USD","LU2236285917.USD","LU0354030438.USD","LU2602419157.SGD","BK4585","LU2491050154.USD","LU2361045086.USD","LU0097036916.USD","LU0006306889.USD","SG9999018857.SGD","BK4007","IE00B4R5TH58.HKD","LU2456880835.USD","LU1551013342.USD","LU2746668974.SGD","LU0114720955.EUR","LU2063271972.USD","LU0109391861.USD","LU1551013425.SGD","LU1623119135.USD","LU2746668461.USD","SG9999014914.USD","LU0354030511.USD","LU1974910355.USD","SGXZ31699556.SGD","LU0096364046.USD","LU2471134879.HKD","LU1868837300.USD","IE00BK4W5L77.USD","LU0256863902.USD","LU1127390331.HKD","LU1366192091.USD","BK4539","LU1868836914.USD","SG9999015945.SGD","BK4563","LU2106854487.HKD","LU0823434583.USD","LU1548497426.USD","LU2237438978.USD","LU0106261372.USD","SGXZ51526630.SGD","LU2750360641.GBP","LU0471298694.HKD","LU2491050071.SGD","LU0323591593.USD","LU2462157665.USD","LU1720051017.SGD","SG9999015978.USD","LU0943347566.SGD","LU0198837287.USD","LU2237443895.HKD","LU1035775433.USD","SG9999013999.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU2324357040.USD","SGXZ99366536.SGD","BK4588","LU0417517546.SGD","IE0002141913.USD","LU1804176565.USD","SG9999014880.SGD","LU1023059063.AUD","LU1983299246.USD","IE0009355771.USD","LU1064131342.USD","LU2112291526.USD","LU0079474960.USD","SGXZ81514606.USD","LU0122379950.USD","SG9999014898.SGD","LU0432979614.USD","LU0820561909.HKD","LU0203202063.USD","LU0672654240.SGD","BK4533","LU2237443465.HKD","LU2237443382.USD","LU2108987350.USD","LU0289739699.SGD","LU1291159041.SGD","BK4599","LU0234572021.USD","LU2417539215.USD","LU2023250504.SGD","LU0256863811.USD","LU1720051108.HKD","LU0708995401.HKD","LU0640476718.USD","SG9999014906.USD","BK4139","LU1232071149.USD","LU1988902786.USD","IE0004445239.USD","IE00BK4W5M84.HKD","IMRX","LU0823416689.USD","LU2552382215.SGD","LU1093756168.USD","LU2552382058.USD","LU0689472784.USD","LU2471134523.USD","LU0456855351.SGD","IE00B1BXHZ80.USD","LU1267930730.SGD","LU1868837136.USD","LU2357305700.SGD","LU0266013472.USD","LU2361044865.SGD","LU2552382132.HKD","LU1917777945.USD","IE00BJLML261.HKD","LU1989771016.USD","LU1868836591.USD","LU1712237335.SGD","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU2360106947.USD","SGXZ57979304.SGD","SG9999001176.USD","BK4581","IE00BJT1NW94.SGD","BK4534","LU1814569148.SGD","LU2361044949.HKD","LU0320765992.SGD","SG9999001176.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2558665081","title":"Immuneering Corporation盘中异动 早盘股价大涨5.23%报3.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558665081","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558665081?lang=zh_cn&edition=full","pubTime":"2025-08-11 21:43","pubTimestamp":1754919822,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日21时43分，Immuneering Corporation股票出现异动，股价快速拉升5.23%。截至发稿，该股报3.42美元/股，成交量4.0251万股，换手率0.11%，振幅5.23%。Immuneering Corporation股票所在的生物技术行业中，整体涨幅为0.17%。Immuneering Corporation公司简介：Immuneering Corp是一家生物制药公司。该公司专有的计算疾病消除技术平台使Immuneering的药物发现计划成为可能。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081121434394dcc40c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081121434394dcc40c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMRX","BK4139","BK4563","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immuneering.com","stockEarnings":[{"period":"1week","weight":-0.0495},{"period":"1month","weight":-0.0459},{"period":"3month","weight":-0.3486},{"period":"6month","weight":-0.1322},{"period":"1year","weight":1.9702},{"period":"ytd","weight":-0.2416}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Immuneering Corporation于2008年在特拉华州注册成立。该公司是一家临床阶段的肿瘤学公司，寻求为广泛的癌症患者群体开发和商业化通用RAS/RAF药物。该公司的目标是通过对MAPK通路的深度循环抑制来实现这种普遍的RAS/RAF活性，在保留健康细胞的同时冲击癌细胞。公司的包容性方法将公司与狭义靶向精准疗法区分开来，后者仅限于携带特定突变的肿瘤患者。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.22671},{"month":2,"riseRate":0.6,"avgChangeRate":-0.02029},{"month":3,"riseRate":0.25,"avgChangeRate":0.059789},{"month":4,"riseRate":0.25,"avgChangeRate":-0.2067},{"month":5,"riseRate":0.25,"avgChangeRate":0.005771},{"month":6,"riseRate":0.75,"avgChangeRate":0.3519},{"month":7,"riseRate":0.75,"avgChangeRate":0.027683},{"month":8,"riseRate":0.4,"avgChangeRate":0.157517},{"month":9,"riseRate":0.8,"avgChangeRate":0.592866},{"month":10,"riseRate":0.2,"avgChangeRate":-0.073665},{"month":11,"riseRate":0.4,"avgChangeRate":-0.104912},{"month":12,"riseRate":0.4,"avgChangeRate":-0.101218}],"exchange":"NASDAQ","name":"Immuneering Corp","nameEN":"Immuneering Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immuneering Corp(IMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Immuneering Corp(IMRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Immuneering Corp,IMRX,Immuneering Corp股票,Immuneering Corp股票老虎,Immuneering Corp股票老虎国际,Immuneering Corp行情,Immuneering Corp股票行情,Immuneering Corp股价,Immuneering Corp股市,Immuneering Corp股票价格,Immuneering Corp股票交易,Immuneering Corp股票购买,Immuneering Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immuneering Corp(IMRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Immuneering Corp(IMRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}